Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atrium TherapeuticsRNA -1.93%12 Days Sales Outstanding is 455.64 as of Jun. 2026, which is 1612% above its 10-year median of 26.62. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 835 Biotechnology companies, Atrium Therapeutics ranks worse than 83.71% on this metric.
Atrium Therapeutics (NAS:RNA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Atrium Therapeutics Days Sales Outstanding Related Terms
Atrium Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Atrium Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNA vs KROS, PLX, GLSI: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Atrium Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrium Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Atrium Therapeutics's Days Sales Outstanding falls into.
Atrium Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 455.64 mean?
Atrium Therapeutics (RNA) has a Days Sales Outstanding of 455.64 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Atrium Therapeutics and its competitors. This is 1612% above median its historical median of 26.62. Over the past decade, Atrium Therapeutics' Days Sales Outstanding has ranged from 25.16 to 152.78. According to the industry distribution chart, Atrium Therapeutics ranks #699 out of 835 companies in the Biotechnology industry, placing it in the top 83.7%.
Is Atrium Therapeutics' Days Sales Outstanding too high?
Atrium Therapeutics' current Days Sales Outstanding of 455.64 is 1612% above median its 10-year median of 26.62. Over the past 10 years, this metric has ranged from a low of 25.16 to a high of 152.78. The Biotechnology industry median Days Sales Outstanding is 68.94. Atrium Therapeutics' value of 455.64 is 560.9% above this industry median. Based on the distribution chart, Atrium Therapeutics ranks #699 out of 835 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Days Sales Outstanding compare to KROS and PLX?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #699 out of 835 companies for Days Sales Outstanding. This places Atrium Therapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Atrium Therapeutics' value of 455.64 is 560.9% above this benchmark. Historically, Atrium Therapeutics' own Days Sales Outstanding has ranged from 25.16 to 152.78 over the past decade. While the company's 10-year median is 26.62 vs. the industry median of 68.94, Atrium Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atrium Therapeutics's current Days Sales Outstanding of 455.64 is 560.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Atrium Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrium Therapeutics's current Days Sales Outstanding is 455.64, which is 1612% above median its own 10-year median of 26.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Days Sales Outstanding of 455.64. The current Days Sales Outstanding is 455.64, which is 1612% above median its 10-year median of 26.62 and 560.9% above the Biotechnology industry median of 68.94. Atrium Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Days Sales Outstanding is 455.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score
Get the complete analysis for RNA
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNA has been successfully added to your 
